The Immune Hallmarks of Severe COVID-19

Researchers are trying to make sense of immune systems gone haywire and develop biomarkers to predict who will become the sickest from a coronavirus infection.

Written byKatarina Zimmer
| 12 min read
covid-19 sars-cov-2 coronavirus pandemic immune response severity severe biomarkers prognostic predictor neutrophil monocyte myeloid cytokine interleukin

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

ABOVE: Scanning electron microscope image of SARS-CoV-2 (gold) emerging from the surface of cells cultured in the lab. The virus shown was isolated from a patient in the US. Image captured and colorized at NIAID’s Rocky Mountain Laboratories (RML) in Hamilton, Montana
FLICKR, NIAID

One of the most striking features of SARS-CoV-2, the virus that causes COVID-19, is the exceptional breadth of symptoms it causes in people. Of the nearly 30 million recorded infections to date, the vast majority of people experienced mild or moderate disease—which itself can range from no symptoms at all to pneumonia or long-term, debilitating neurological symptoms. A minority ended up with severe respiratory symptoms but eventually recovered. And some—nearly 940,000 worldwide, of which 196,000 are in the US—took a turn for the worse and died.

Why some people die while others recover is thought to depend in large part on the human immune response, which spirals ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform